SEC Filings
Structure Therapeutics Research Costs Climb To $134.6 Million From $59 Million As Trial Spending Rises
The oral obesity drug developer expects its cash to last through 2028, excluding commercial preparation and manufacturing costs.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
SEC Filings
The oral obesity drug developer expects its cash to last through 2028, excluding commercial preparation and manufacturing costs.
SEC Filings
Production beat the forecast midpoint, and Occidental paid down $1.8 billion of principal debt to reach $10.0 billion.
Earnings
Sales rose 39%, but meeting the annual revenue forecast requires roughly 37% to 52% growth in the fourth quarter.
Earnings
Revenue rose approximately 140%, while spending on the commercial organization and new monitors increased.
SEC Filings
Jane Street Capital holds most of the reported position; the group says its holdings are not intended to influence control.
Earnings
Loss per share narrowed, while initial results from the completed depression-study enrollment are now expected in December.
Markets
Deramiocel met its upper-limb trial goal, but a cardiac measure missed statistical significance and FDA approval remains pending.
SEC Filings
CRH guarantees the debt, which carries interest rates ranging from 5.375% to 6.250%.
Markets
The rebound added $356 million in market value, following a slide that left shares down 45% for the year at Friday's close.
SEC Filings
Unused bilateral capacity fell even as overall credit availability increased, with buybacks and plant investments drawing on cash.
SEC Filings
The passive ownership report covers September 30, with Goldman certifying that its holding was not intended to influence control.
SEC Filings
Banasino Establishment became the holding company's sole shareholder; the reporting entities retained conditional options for a deal.